Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Improving anti-tumor immunity in advanced breast cancer by targeting solid stress

Award Number: R01CA284133
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

Improving anti-tumor immunity in advanced breast cancer by targeting solid stress - Project Summary Response rates to current immunotherapies are comparably low in breast cancer patients, yet patients with T cell infiltrates often respond better. To improve the response rates of breast cancer patients to immunotherapy, it is imperative to develop strategies that enhance T cell infiltration. In a recent study, we demonstrated that cancer cells compress blood vessels within metastatic breast tumors and impair the recruitment of T cells into these tumors. Losartan, an antihypertensive and antifibrotic drug, reduced extracellular matrix production in metastatic breast tumors, normalized blood vessels, and promoted T cell accumulation in tumors. Based on these findings, we hypothesize that the angiotensin receptor blocker (ARB) losartan decompresses the tumor vasculature and promotes T cell trafficking into mouse breast cancers. To test this hypothesis, we will use a lymph node window that allows in vivo imaging for two weeks. With the window, we will use optical coherence tomography imaging to measure tissue compression and blood vessel function within primary and lymph node tumors (Aim 1). In addition, we will use multiphoton microscopy imaging and adoptive transfer studies to test our hypothesis that losartan promotes naïve and cancer specific T cell entry into decompressed vessels in primary and lymph node tumors (Aims 1 and 2). Further, our experiments are designed to uncover how losartan, combined with immunotherapy to enhance T cell function, leads to the eradication of breast tumors (Aim 2). We will use single cell RNA sequencing and flow cytometry to examine the composition and transcriptional signatures of cells in the reprogrammed tumors responding to combination therapy. Finally, we will test whether T cells are sufficient for tumor growth delay. Based on preliminary data from animal studies, we hypothesize that the use of ARBs, such as losartan, by breast cancer patients is associated with reduced extracellular matrix deposition in tumors and enhanced T cell infiltration into tumors. To study if ARB use is associated with these predicted outcomes, we will use patient specimens from women enrolled in the Black Women’s Health Study (BWHS), including those who took ARBs at the time of diagnosis. In Aim 3, we will use multiplex staining and quantitative multispectral imaging to investigate extracellular matrix deposition, vascular structure, and immune cell infiltration in 554 invasive breast cancer samples. A bioinformatic analysis of RNA-sequencing data obtained from invasive breast cancer samples will be performed to investigate transcriptomic signatures associated with cells in the tumor microenvironment. We will measure whether our findings from ARB-naïve patients and ARB users strongly associate with survival and other clinicopathological characteristics. We anticipate that successful completion of the proposed studies by our multidisciplinary team will reveal the clinical utility of ARBs as a potential strategy to increase T cell entry into breast tumors and improve the disconcerting response rates to current immunotherapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $505,322 )
2026	2026	TRUSTEES OF BOSTON UNIVERSITY	85 EAST NEWTON ST # M-921	BOSTON	MA	02118	SUFFOLK	USA	Cancer Biology Research	000	3	6/9/2026	NON-COMPETING CONTINUATION	$505,322
														Subtotal = $505,322

Issue Date FY: 2025 ( Subtotal = $421,414 )
2025	2025	TRUSTEES OF BOSTON UNIVERSITY	85 EAST NEWTON ST # M-921	BOSTON	MA	02118	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	2	7/18/2025	NON-COMPETING CONTINUATION	$421,414
2025	2024	TRUSTEES OF BOSTON UNIVERSITY	85 EAST NEWTON ST # M-921	BOSTON	MA	02118	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	4/16/2025	NEW	$0
														Subtotal = $421,414

Issue Date FY: 2024 ( Subtotal = $451,940 )
2024	2024	TRUSTEES OF BOSTON UNIVERSITY	85 EAST NEWTON ST # M-921	BOSTON	MA	02118	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	5/15/2024	NEW	$451,940
														Subtotal = $451,940

Grand Total All Awards = $1,378,676

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Improving anti-tumor immunity in advanced breast cancer by targeting solid stress

Award Number: R01CA284133

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer